Hence, these findings do not exclude that IL-6R inhibition may yield clinically significant benefits on glucose metabolism in groups of people at risk for T2D, or on glycaemic levels and risk of complications in patients with T2D. This evidence concerns the gene IL6R and type 2 diabetes mellitus.